Reflections on AACC/ADLM 2023

At the AACC 2023 Clinical Lab Expo that was held at the Anaheim Convention Center in Anaheim, California, from July 23-27, the American Association for Clinical Chemistry (AACC) announced its new name, the Association for Diagnostics & Laboratory Medicine (ADLM).

More than 900 exhibitors that covered over 200 product categories attracted IVD leaders and lab professionals from around the world. Presented solutions comprised immunoassays, molecular diagnostics, hematology, blood gas monitoring, microbiology, mass spectrometry, translational medicine and lab management, among others. Mid- to high throughput and solutions for point-of-care diagnostics were on display. 

As presented at the International Marketing Briefing by IQVIA, the 2022 IVD market slowed after robust gains since the start of the pandemic (2022: $118 billion compared to $129 billion in 2021). To drive future growth, IVD companies have been striving to expand assay menus on their instruments, thereby adding more value to the installed instruments base in laboratories across the globe. 

In general, a larger number of smaller instruments for mid- to low throughput capacity and many new assays were showcased. Alongside most of the top 20+ established IVD players, and similar to EuroMedLab 2023 in Rome, an increased and high number of exhibitors from China showcased instruments and reagents that are not approved for sale in the U.S.  

Several core lab systems and instruments for the point of care from the top 20+ IVD companies, including Volpi-developed and -manufactured optical measurement solutions, could be seen. These solutions comprise low-, mid- and high throughput clinical chemistry platforms with all LED digital imaging, LED/halogen illumination and spectroscopic detection; immunoassay hematology solutions; and high-multiplex molecular diagnostics instruments.     

The 2023 ADLM Disruptive Technology Award was given to Pattern Bioscience for their single-cell microbiology solutions. Vital Biosciences Inc. was selected as the Audience Choice for their integrated diagnostics platform, VitalOne, which can detect 50+ analytes in 20 minutes at the point of care. Volpi Group is proud to have contributed to all three instrument subsystems in VitalOne: hematology, clinical chemistry and immunoassays.